In Open Access
Now anyone who wishes can learn the results of clinical trials of drugs, approved in the EU. European Medicines Agency (EMA) has opened access to these.
According to Vitenis Andriukaitis, European Union Commissioner on Healthcare and Product Safety, transparency of clinical trials is the key component. Study results, whether positive or negative, should be in open access. That is why wider public is offered an opportunity to see documents submitted (as of January 1, 2015) by pharmaceutical companies for marketing authorization of drugs to the European Medicines Agency.
Over 260 thousand pages containing information and over 100 clinical trials of two drugs have already been uploaded.
The database will be sourced with clinical study reports of other drugs. Study information and results will be uploaded to the on-line resourced within 60 days after approval of a drug for marketing authorization in EU.
This will be a continuous process. Information on approximately 4.5 thousand clinical trials will be uploaded to the database annually.